CN100350979C - 核酸和血管活性剂相组合用于加强的基因投递 - Google Patents

核酸和血管活性剂相组合用于加强的基因投递 Download PDF

Info

Publication number
CN100350979C
CN100350979C CNB998049425A CN99804942A CN100350979C CN 100350979 C CN100350979 C CN 100350979C CN B998049425 A CNB998049425 A CN B998049425A CN 99804942 A CN99804942 A CN 99804942A CN 100350979 C CN100350979 C CN 100350979C
Authority
CN
China
Prior art keywords
vector
injection
histamine
fgf
artery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998049425A
Other languages
English (en)
Chinese (zh)
Other versions
CN1301181A (zh
Inventor
H·K·哈蒙德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, San Diego filed Critical University of California, San Diego
Publication of CN1301181A publication Critical patent/CN1301181A/zh
Application granted granted Critical
Publication of CN100350979C publication Critical patent/CN100350979C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Paints Or Removers (AREA)
CNB998049425A 1998-02-11 1999-02-09 核酸和血管活性剂相组合用于加强的基因投递 Expired - Fee Related CN100350979C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2177398A 1998-02-11 1998-02-11
US09/021,773 1998-02-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2007101808364A Division CN101186928A (zh) 1998-02-11 1999-02-09 核酸和血管活性剂相组合用于加强的基因投递

Publications (2)

Publication Number Publication Date
CN1301181A CN1301181A (zh) 2001-06-27
CN100350979C true CN100350979C (zh) 2007-11-28

Family

ID=21806073

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB998049425A Expired - Fee Related CN100350979C (zh) 1998-02-11 1999-02-09 核酸和血管活性剂相组合用于加强的基因投递
CNA2007101808364A Pending CN101186928A (zh) 1998-02-11 1999-02-09 核酸和血管活性剂相组合用于加强的基因投递

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2007101808364A Pending CN101186928A (zh) 1998-02-11 1999-02-09 核酸和血管活性剂相组合用于加强的基因投递

Country Status (11)

Country Link
EP (2) EP1053025A2 (cg-RX-API-DMAC7.html)
JP (1) JP2002502885A (cg-RX-API-DMAC7.html)
KR (1) KR20010015915A (cg-RX-API-DMAC7.html)
CN (2) CN100350979C (cg-RX-API-DMAC7.html)
AU (1) AU2663799A (cg-RX-API-DMAC7.html)
CA (1) CA2320302A1 (cg-RX-API-DMAC7.html)
EA (1) EA019099B1 (cg-RX-API-DMAC7.html)
IL (1) IL137765A0 (cg-RX-API-DMAC7.html)
NZ (1) NZ545047A (cg-RX-API-DMAC7.html)
WO (1) WO1999040945A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA991102B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6752987B1 (en) 1995-02-28 2004-06-22 The Regents Of The University Of California Adenovirus encoding human adenylylcyclase (AC) VI
US20020103147A1 (en) 1997-09-05 2002-08-01 Hammond H. Kirk Gene therapy for congestive heart failure
WO2000024415A2 (en) 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using trk receptor ligands
HK1048593A1 (zh) * 1999-11-05 2003-04-11 The Regents Of The University Of California 用於通过体内基因输送治疗心血管疾病的技术和组合物
CA2412847A1 (en) * 2000-06-30 2002-01-10 Collateral Therapeutics, Inc. Dual recombinant gene therapy compositions and methods of use
JP2005052001A (ja) * 2001-07-05 2005-03-03 Takara Bio Inc 遺伝子治療剤
EP2236153A3 (en) 2005-01-25 2012-08-22 Five Prime Therapeutics, Inc. Compositons and methods for treating cardiac conditions
PL2044199T3 (pl) * 2006-07-25 2013-04-30 Celladon Corp Przedłużony, podawany z prądem krwi, nasierdziowy, wieńcowy wlew wektorów wirusowych na bazie wirusów towarzyszących adenowirusom, zawierający SERCA2a do terapii genowej
JP5290290B2 (ja) 2007-07-18 2013-09-18 シルク・ロード・メディカル・インコーポレイテッド 頚動脈血流の逆流を確立する方法およびシステム
EP2244740A1 (en) 2008-02-19 2010-11-03 Celladon Corporation Compositions for enhanced uptake of viral vectors in the myocardium
US20130096500A1 (en) * 2011-07-07 2013-04-18 Gabor Rubanyi Nucleic acid based cardiovascular therapeutics
WO2014160887A2 (en) * 2013-03-28 2014-10-02 Silk Road Medical, Inc. Methods and systems for establishing retrograde carotid arterial blood flow
WO2019089385A1 (en) 2017-11-02 2019-05-09 Silk Road Medical, Inc. Fenestrated sheath for embolic protection during transcarotid carotid artery revascularization

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026742A1 (en) * 1995-02-28 1996-09-06 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
WO1996030535A1 (en) * 1995-03-30 1996-10-03 Beth Israel Deaconess Medical Center, Inc. Gene transfer into the kidney

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999017807A1 (en) * 1997-10-08 1999-04-15 Cobra Therapeutics Ltd. Use of a vasoactive compound in the enhancement of gene delivery
WO1999018792A1 (en) * 1997-10-10 1999-04-22 Johns Hopkins University Gene delivery compositions and methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026742A1 (en) * 1995-02-28 1996-09-06 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
WO1996030535A1 (en) * 1995-03-30 1996-10-03 Beth Israel Deaconess Medical Center, Inc. Gene transfer into the kidney

Also Published As

Publication number Publication date
CA2320302A1 (en) 1999-08-19
WO1999040945A2 (en) 1999-08-19
ZA991102B (en) 2000-03-31
IL137765A0 (en) 2001-10-31
WO1999040945A3 (en) 1999-09-30
EP1695719A1 (en) 2006-08-30
CN101186928A (zh) 2008-05-28
CN1301181A (zh) 2001-06-27
JP2002502885A (ja) 2002-01-29
EA200000828A1 (ru) 2001-02-26
AU2663799A (en) 1999-08-30
EA019099B1 (ru) 2014-01-30
KR20010015915A (ko) 2001-02-26
EP1053025A2 (en) 2000-11-22
NZ545047A (en) 2009-05-31

Similar Documents

Publication Publication Date Title
CN1136920C (zh) 基因转移介导的血管形成疗法
US5792453A (en) Gene transfer-mediated angiogenesis therapy
US20090082293A1 (en) Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
US20080254109A1 (en) Localized myocardial injection method for treating ischemic myocardium
AU784392B2 (en) Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
CA2289600C (en) Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes
CN101186928A (zh) 核酸和血管活性剂相组合用于加强的基因投递
CA2412847A1 (en) Dual recombinant gene therapy compositions and methods of use
AU2006200170B2 (en) Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
AU706050C (en) Gene transfer-mediated angiogenesis therapy
HK1094944A (en) Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
AU2006235836A1 (en) Gene transfer-mediated angiogenesis therapy
AU4754199A (en) Gene transfer-mediated angiogenesis therapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1068302

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20071128

Termination date: 20170209

CF01 Termination of patent right due to non-payment of annual fee